Analysis of MIC and disk diffusion testing variables for gepotidacin and comparator agents against select bacterial pathogens
LM Koeth, JM DiFranco-Fisher… - Journal of Clinical …, 2017 - Am Soc Microbiol
This study was conducted to determine the effect of testing parameters on the in vitro activity
of gepotidacin, a new triazaacenaphthylene antibacterial agent for the treatment of …
of gepotidacin, a new triazaacenaphthylene antibacterial agent for the treatment of …
Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria
RK Flamm, DJ Farrell, PR Rhomberg… - Antimicrobial agents …, 2017 - Am Soc Microbiol
Gepotidacin is a first-in-class, novel triazaacenaphthylene antibiotic that inhibits bacterial
DNA replication and has in vitro activity against susceptible and drug-resistant pathogens …
DNA replication and has in vitro activity against susceptible and drug-resistant pathogens …
[HTML][HTML] Intermethod comparability analyses of gepotidacin antimicrobial susceptibility tests using a large collection of globally collected Escherichia coli and …
SJR Arends, D Butler, N Scangarella-Oman… - … and Infectious Disease, 2024 - Elsevier
Gepotidacin (GSK2140944) is a novel, bactericidal, first in class triazaacenaphthylene
bacterial type II topoisomerase inhibitor in development for the treatment of uncomplicated …
bacterial type II topoisomerase inhibitor in development for the treatment of uncomplicated …
In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes
MA Hackel, JA Karlowsky, MA Canino… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial
currently in phase III clinical trials. When tested against Gram-negative (n= 333) and Gram …
currently in phase III clinical trials. When tested against Gram-negative (n= 333) and Gram …
Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
BD VanScoy, EA Lakota, H Conde… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial
DNA replication by a distinct mechanism of action with an in vitro spectrum of activity that …
DNA replication by a distinct mechanism of action with an in vitro spectrum of activity that …
[HTML][HTML] Analysis of the effect of urine on the in vitro activity of gepotidacin and levofloxacin against Escherichia coli, Staphylococcus epidermidis, and Staphylococcus …
LM Koeth, JM DiFranco-Fisher… - … and Infectious Disease, 2023 - Elsevier
Gepotidacin is a novel agent in development for treatment of gonorrhea and uncomplicated
urinary tract infection. This study determined the effect of urine on the in vitro activity of …
urinary tract infection. This study determined the effect of urine on the in vitro activity of …
Pharmacokinetic-pharmacodynamic evaluation of gepotidacin against Gram-positive organisms using data from murine infection models
CC Bulik, ÓO Okusanya, EA Lakota… - Antimicrobial Agents …, 2017 - Am Soc Microbiol
Gepotidacin (formerly called GSK2140944) is a novel triazaacenaphthylene bacterial
topoisomerase inhibitor with in vitro activity against conventional and biothreat pathogens …
topoisomerase inhibitor with in vitro activity against conventional and biothreat pathogens …
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and …
NE Scangarella-Oman, KA Ingraham… - Antimicrobial Agents …, 2020 - Am Soc Microbiol
ABSTRACT A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany
M Kresken, E Wohlfarth, C Weikel… - Journal of …, 2023 - academic.oup.com
Background Escherichia coli is the leading pathogen of community-acquired urinary tract
infections. Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene oral …
infections. Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene oral …
Efficacy of Human Exposures of Gepotidacin (GSK2140944) against Escherichia coli in a Rat Pyelonephritis Model
JL Hoover, CM Singley, P Elefante… - Antimicrobial Agents …, 2019 - Am Soc Microbiol
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial that inhibits bacterial type II
topoisomerases and has in vitro activity against a range of bacterial pathogens, including …
topoisomerases and has in vitro activity against a range of bacterial pathogens, including …